Rhythm Pharmaceuticals Balances Strong Growth With Rising Costs
Rhythm Pharmaceuticals ((RYTM)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rhythm Pharmaceuticals’ latest earnings call mixed strong commercial momentum with a candid view of growing costs and execution risks. Management highlighted roughly 50% full‑year revenue growth, expanding global reach and encouraging obesity drug data, while also warning that larger Phase 3 trials, higher operating expenses and reimbursement lags will weigh on near‑term margins.
Robust Top-Line Growth in Q4 and Full Year
Rhythm posted Q4 2025 product revenue of $57.3 million, up 12% sequentially and 37% year over year, underscoring sustained demand for IMCIVREE. Full‑year 2025 revenue reached $194.8 million, representing about 50% growth versus 2024 and giving investors confidence that the commercial base is scaling.
Expanding Patient Base and International Mix
Quarterly growth was fueled by an estimated 10% increase in patients on reimbursed therapy globally in Q4 2025, pointing to deeper market penetration. The U.S. generated 68% of Q4 sales at $39 million while ex‑U.S. markets delivered $18.3 million, with international revenue up roughly 40% versus Q3.
Bivamelagon Shows Durable 40-Week Efficacy
Phase 2 open‑label data for bivamelagon revealed durable weight loss, with mean BMI reductions of 10.8% at 400 mg and 14.3% at 600 mg over 40 weeks, even including non‑compliant patients. Notably, 11 of 14 patients in the higher‑dose cohorts saw BMI cut by at least 10%, supporting the drug’s potential in severe obesity.
Regulatory Green Light for Phase 3 in HO
An End‑of‑Phase‑2 meeting with the FDA concluded that bivamelagon is ready to enter Phase 3 for hypothalamic obesity. Rhythm plans a 12‑month randomized controlled trial aligned with regulators and intends to leverage the full 142‑patient dataset in future labeling discussions.
Pipeline of Near-Term Regulatory Catalysts
Investors face a packed catalyst calendar, with a key regulatory decision for acquired hypothalamic obesity due in March 2026. Additional milestones include Japanese HO data and an M&A readout in March, a European CHMP opinion in the second quarter and potential EU marketing authorization in the second half of 2026.
International Expansion and Scientific Visibility
IMCIVREE is now available in more than 25 countries outside the U.S., supported by an ex‑U.S. team of over 100 employees across 13 countries and eight new markets added in 2025. Scientific presence also expanded, with 64 abstracts accepted at 12 major congresses, strengthening Rhythm’s positioning with specialists.
Preparing the Field for an AHO Launch
To support a potential U.S. launch in acquired hypothalamic obesity, the sales force was expanded sharply from 16 to 42 representatives. Field teams have already engaged healthcare providers caring for more than 2,000 diagnosed or suspected AHO patients and identified around 40 priority centers where care is concentrated.
Solid Cash Position and Funding Runway
The company ended 2025 with roughly $389 million in cash, cash equivalents and short‑term investments, after using $116 million in operating cash over the year. Rhythm believes this balance sheet can fund its planned operations for at least the next 24 months, even as spending rises.
Broad Clinical Development Momentum
Beyond bivamelagon, Rhythm is advancing a weekly RM‑718 formulation with initial three‑month data expected by mid‑year, aiming to improve convenience. Its Prader‑Willi syndrome trial remains on track, with 17 of 18 patients still on treatment and six‑month data also slated for mid‑year as next‑generation compound supplies are readied for Phase 3.
FDA Demands Larger, Longer Phase 3 Program
The FDA signaled that bivamelagon, as a new chemical entity, must undergo a full 12‑month double‑blind Phase 3 trial and a larger safety database, echoing the roughly 142‑patient setmelanotide program. This requirement will likely extend development timelines and increase trial costs, adding to Rhythm’s capital needs.
Inventory Dynamics Could Temper Near-Term Revenue
Specialty pharmacy inventory days rose to about 20 versus a 10–15 day norm, with 1.7 million more vials shipped than dispensed in Q4, down from 3 million in Q3. This inventory build created a negative $1.3 million swing and management cautioned it could modestly dampen reported Q1 revenue as stocks normalize.
Operating Expenses Climb Into 2026
GAAP operating expenses in 2025 totaled $362.3 million, including $66.8 million of stock‑based compensation, reflecting investment in R&D and commercialization. For 2026, Rhythm guided non‑GAAP operating expenses to $385 million to $415 million, about 35% above 2025 at the midpoint, driven by formulations, clinical supply and global launch preparations.
Growing SG&A and Persistent Net Losses
Selling, general and administrative costs surged to $57.5 million in Q4 2025 from $38.1 million a year earlier, a jump of about 51% as the company scaled its commercial footprint. The heavier cost base left Rhythm with a GAAP net loss of $0.73 per share in the quarter and ongoing cash burn of roughly $25 million.
Risks Around Genetic Substudies
Management flagged uncertainty around certain EMANATE genetic substudies, where uneven enrollment and complex biology could yield weaker signals. Under‑enrollment in cohorts such as LEPR and many variants of unknown significance in SRC1 raise the odds that some readouts may be negative or inconclusive.
Access and Reimbursement Timing Challenges
Even with potential approvals, the company expects payer coverage for acquired hypothalamic obesity to take three to nine months as policies get updated. Outside the U.S., country‑by‑country reimbursement and health technology assessments may further delay broad access, creating a lag between regulatory wins and revenue.
Potential Dilution from Convertible Preferred Stock
Rhythm also acknowledged a sizable potential overhang from its remaining convertible preferred shares, which could translate into more than 200 million common shares if fully converted. Recent conversions reduced part of the dividend burden but still leave investors facing meaningful dilution risk over time.
Compliance and Formulation Hurdles in Younger Patients
The Phase 2 bivamelagon trial exposed adherence issues among younger teenagers, largely due to large pill sizes that are hard to swallow. The company is developing new single‑pill and chewable formulations, but further bioequivalence and formulation work is needed before these can feed into Phase 3 plans.
Guidance and Outlook
Management’s 2026 guidance calls for non‑GAAP operating expenses of $385 million to $415 million, with R&D at $197 million to $213 million and SG&A at $188 million to $202 million to support next‑gen formulations, a U.S. HO launch and a Japan build‑out. Key upcoming events include a March 2026 PDUFA for acquired HO, mid‑year RM‑718 and PWS data, European decisions later in 2026 and initiation of a pivotal HO Phase 3 trial by year‑end.
Rhythm’s earnings call painted a picture of a company leaning aggressively into growth, with strong revenue momentum, expanding international reach and promising obesity data offset by rising costs and trial complexity. For investors, the story hinges on execution: converting scientific and regulatory wins into sustainable, reimbursed revenue while managing dilution and cash burn.
